BridgeBio Oncology Therapeutics (BBOT) investor relations material

Executive summary

• Clinical-stage RAS and PI3K oncology pipeline; BBO-8520, BBO-10203 and BBO-11818 are in Phase 1, with no approved products or product sales.

• BBO-8520 plus pembrolizumab showed clinical activity and a potentially differentiated liver-safety profile; expanded data in 2L+ KRASG12C inhibitor-experienced NSCLC expected mid-2027.

• Strategic focus shifted to BBO-8520/checkpoint-inhibitor and BBO-11818/BBO-10203 combinations in KRAS-mutant cancers.

Financial highlights

• Q3 2026 net loss was $34.2M vs. $44.8M; loss per share was $0.43 vs. $1.03.

• Q3 R&D was $29.6M vs. $35.1M, and G&A was $7.9M vs. $14.1M; lower trial and consumables costs followed program prioritization, while prior-year G&A included a $7.8M related-party share charge.

• 9M 2026 net loss was $132.7M vs. $95.2M; R&D was $118.6M vs. $83.1M and G&A was $25.2M vs. $19.3M, reflecting expanded development investment.

• 9M R&D growth included higher trial and manufacturing costs across the three lead candidates, as well as increased headcount and stock-based compensation.

Outlook and guidance

• Cash, cash equivalents and marketable securities totaled $315.3M at September 30, 2026, with runway estimated into 2029; estimates depend on assumptions and funds could be consumed sooner.

• BBO-11818 and BBO-10203 monotherapy updates are expected in Q4 2026; combination data in CRC and PDAC and expanded BBO-8520 combination data are expected mid-2027.

• Significant expenses and operating losses are expected to continue; additional capital may be needed, potentially diluting holders or delaying or reducing programs.